PTGX (Protagonist Therapeutics) Short Interest


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $122.36
GF Value $55.69
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PTGX vs SYRE, CELC, MIRM: Short Interest Comparison

For the Biotechnology subindustry, Protagonist Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagonist Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Short Interest falls into.


PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $122.36 is trading 119.7% above its estimated GF Value™ of $55.69. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • Short Interest:
  • GF Value™: $55.69 vs. price of $122.36 (119.7% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.36
Price
$55.69
GF Value